Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryo Dairiki
Observed names:
R Dairiki,
R. Dairiki
Institution:
Eisai (Japan)
Observed institutions:
Japan Science and Technology Agency,
Takeda (Japan),
Eisai (Japan),
The University of Tokyo
OpenAlex ID:
A5011214168
Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging
2012
·
Fumihito Miura
, Yusuke Enomoto
, et al.
·
Nucleic Acids Research
·
459
PDF
Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing
2015
·
Shinsuke Araki
, Ryo Dairiki
, et al.
·
PLoS ONE
·
138
PDF
A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells
2016
·
Yoshinori Ishikawa
, Kanae Gamo
, et al.
·
Molecular Cancer Therapeutics
·
117
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
2018
·
Kenichi Iwai
, Masahiro Yaguchi
, et al.
·
EMBO Molecular Medicine
·
111
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2021
·
Richard S. Finn
, Masatoshi Kudo
, et al.
·
Clinical Cancer Research
·
86
PDF
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
2019
·
Kenichi Iwai
, Tadahiro Nambu
, et al.
·
Science Advances
·
73
Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
2017
·
Y Ishikawa
, K Nakayama
, et al.
·
Oncogenesis
·
43
PDF
Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
2018
·
R.S. Finn
, M. Kudo
, et al.
·
Annals of Oncology
·
29
PDF
Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
2017
·
R.S. Finn
, M. Kudo
, et al.
·
Annals of Oncology
·
15
Discovery and characterization of stereodefined PMO-gapmers targeting tau
2024
·
Kunihiko Kanatsu
, Yoshinori Takahashi
, et al.
·
Molecular Therapy — Nucleic Acids
·
12
In vitro and in vivo functions of T cells produced in complemented thymi of chimeric mice generated by blastocyst complementation
2022
·
Kazuto Yamazaki
, Kenji Kubara
, et al.
·
Scientific Reports
·
9
PDF
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.
2018
·
Vicky Makker
, Allen Lee Cohn
, et al.
·
Journal of Clinical Oncology
·
5
Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
2018
·
C.-H. Lee
, R.J. Motzer
, et al.
·
Annals of Oncology
·
3
Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
Supplementary Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
Supplementary Excel_nCounter PanCancer Human Pathways Panel Gene List from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
2024
·
Richard S. Finn
, Masatoshi Kudo
, et al.
Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
2019
·
Y. Ishikawa
, K. Nakayama
, et al.
·
Oncogenesis
PDF
Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931
2017
·
Kenichi Iwai
, Tadahiro Nambu
, et al.
·
Cancer Research
Show more works
View as search
Works count:
18
Citation count:
1,100
H-index:
10
I10-index:
10
Year
Topic
Type